- CRC data on cord lining media for the treatment of diabetic foot ulcers has been accepted at the DFCon, with Dr Wong Keng Lin Francis, CRC s latest KOL,.
/PRNewswire/ CellResearch Corporation, a Singapore-based biopharmaceutical company today announced it has successfully closed the first Phase I study in.
SINGAPORE, Sept. 17, 2022 /PRNewswire/ CellResearch Corporation, a Singapore-based biopharmaceutical company today announced it has successfully closed the first Phase I study in CorLiCyte®, a stem cell therapy derived from umbilical cord lining stem cells, with research partners at the University of Colorado, Anschutz Medical Campus and ClinImmune Cell and Gene Therapy. CorLiCyte® is in development for the.